Satohiro Masuda presents the agenda of the committee. Due to the physical absence of many members like the meeting in 2021 at Rome, no formal vote on discussed points was organized during the meeting. Final approval of the points discussed will be sent by e-mail to everyone for their comments.

The ISD committee received application of Vincent Haufroid, Tomoyuki Mizuno, Natalia Riva and Judith Taibon for joining the committee.

Because of no more active membership, David Holt was removed from the list of e-mail address.

Annual general meeting
The annual general meeting has been sent to everyone for validation before being made available on the IATDMCT website.

Working groups under this committee:
- Three working groups were confirmed under ISD committee.
  - Biomarkers (Christians)
  - Standardization of iSD TDM working groups (Seger, Langman)
  - Intracellular tacrolimus concentrations (Lemaitre)

Publications:
Consensus paper on everolimus is being written (leadership is Satohiro)

Suggested next publication: consensus paper on cyclosporine, is particularly needed (proposed and coordinated by Uwe Christians).

Suggested next publication: new biomarker paper, as update from working group (M. Brunet proposes new multicenter study, and not a new review paper. Oellerich stresses the progress made with cfDNA, is already reimbursed in US, and need for RCTs demonstrating clinical utility. Christians
mentions the need for critical review of literature on cfDNA in organ transplantation (critical gap analysis). Brunet proposes review paper on microRNAs. After some discussion Christians proposes to coordinate a comprehensive review paper in which a range of different biomarkers will be reviewed including cfDNA and miRNA as well as development of Donor Specific Antibodies in relation to immunosuppressive drug exposure. But these proposals would be more discussed with members not physically attended the business meeting.

Suggested next publication, special theme on TDM for biologics. Action: ask the chair of the Scientific Committee for TDM of biologics.

**Education:** there has not been much progress yet, will come back at future meeting. Bergan mentions that Jorie Versmissen is exploring EU funding for teaching MDs and nurses on TDM and clinical pharmacology. Is linked to the MOOC on transplantation initiated by Leiden? Check out: [https://www.boerhaavenascholing.nl/medische-nascholing/2021/mooc-online-course-clinical-kidney-pancreas-and-islet-transplantation/](https://www.boerhaavenascholing.nl/medische-nascholing/2021/mooc-online-course-clinical-kidney-pancreas-and-islet-transplantation/)

Ask Dirk Jan Moes (action van Gelder).

**Initiative for runbook for routine practice.** Masuda mentions that there are TDM guidance documents in Japan, that could be made available for IATDMCT members after translation. Van Gelder mentions that a similar initiative is now being rolled out based on the late Eric van Maarseveen. (Masuda will check with Christoph Stove)

**Compass:** Natalia Riva stresses the possibility to publish in Compass, for example interesting case reports where TDM or toxicology cases are discussed (action Natalia Riva to send invitation to Masuda).